3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
10
Renal Insufficiency
1
Recurrence
1
Neoplasms, Plasma Cell
1
Kidney Failure, Chronic
1
Interventions
Cyclophosphamide
41
fludarabine
31
Dexamethasone
27
venetoclax
24
Cytarabine
22
Rituximab
16
pembrolizumab
15
fludarabine phosphate
14
Filgrastim
12
Etoposide
12
Lenalidomide
11
Vincristine
10
Gemcitabine
10
Azacitidine
10
pomalidomide
9
Interleukin-2
9
Granulocyte Colony-Stimulating Factor
9
Doxorubicin
9
Calcium Dobesilate
9
carfilzomib
8
Topotecan
8
Nivolumab
8
Methotrexate
8
Everolimus
8
Decitabine
8
Bortezomib
8
Melphalan
7
Cisplatin
7
Vorinostat
6
Injections
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Recurrence
×
belantamab mafodotin
×
Clear all
NCT04398680
2025-12-04
DREAMM 13
GlaxoSmithKline
Phase 1
Withdrawn